A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors
NCT01738451
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
GSK2118436 75 mg
DRUG:
Placebo
Sponsor
GlaxoSmithKline